StockWatch
·

Fermenta Biotech Ltd

BSE: 506414

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
120.59
+3.3%+7.1%
Expenditure
101.82
+5.4%+10.8%
Net Profit
13.95
-6.9%-5.2%
OPM %
20.56%
+0.02pp-0.88pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0041.5783.14124.72166.29Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Fermenta Biotech Q2 FY27: consolidated PAT down 48% YoY, NPM compresses to 6.9%

bulk drugs chemicals · vitamin b12 · overseas subsidiary losses

ResultsQ2 FY2705 Nov 20263 minPharma & Healthcare

Fermenta Biotech Q1 FY27: consolidated PAT down 56% YoY as margins nearly halve

vitamin d3 api · bulk drugs chemicals · margin compression

ResultsQ1 FY2711 Aug 20263 minPharma & Healthcare
Latest
Quarterly Result5 Nov, 1:00 pm

Fermenta Biotech Q2 FY27: consolidated PAT down 48% YoY, NPM compresses to 6.9%

Fermenta Biotech's consolidated (primary basis) PAT fell 47.7% YoY to ₹9.44 Cr even as consolidated revenue was nearly flat, up just 1.9% YoY to ₹132.67 Cr from ₹130.22 Cr — profit growth trailed revenue growth by a wide margin, and NPM compressed to 6.95% from 13.29% a year ago (also down from 7.55% in Q1 FY27). Standalone (secondary basis) tells a materially milder story: standalone PAT fell only 5.2% YoY to ₹13.95 Cr on 9.2% YoY revenue growth to ₹116.94 Cr, a >40-percentage-point gap in PAT growth versus the consolidated print. Readers comparing the two numbers should not assume either is wrong — the divergence is explained below. The margin squeeze sits mainly below the core operating line: the core bulk drugs/chemicals segment, which is the real operating engine, saw its segment profit fall 28.5% YoY to ₹18.98 Cr (from ₹26.55 Cr) even as segment revenue rose, implying cost pressure within the core business itself. On top of that, the company's three overseas units (UK, Germany, US) swung to a combined ₹2.71 Cr net loss this quarter per the statutory auditor's review note — a drag that doesn't show up in the standalone numbers — while the Environment segment (housed in subsidiary FESPL) added a further ₹1.76 Cr segment loss, narrower than Q1's ₹2.71 Cr loss but still a drag. Finance costs rose to ₹3.73 Cr from ₹2.58 Cr a year ago, adding to the pressure. Operating margin (profit before tax and finance cost over revenue from operations) eased to roughly 13.6% from about 20.5% YoY. There is no formal management guidance on record for this quarter — neither in our database nor in the filing itself — and no management press release was available to extract commentary from, so there is nothing from the company to grade this print against. A web search for analyst/consensus estimates ahead of this result found none specific to Fermenta Biotech's Q2 FY27 (results were approved and released the same day as the search, and the stock has thin formal sell-side coverage), so vsStreet is unknown rather than assumed. Sequentially, revenue grew 8.9% QoQ to ₹132.67 Cr but PAT was essentially flat, down 1.0% QoQ to ₹9.44 Cr from ₹9.53 Cr, consistent with a business where topline recovery hasn't yet translated into profit recovery. Separately, during the quarter promoter-linked holder Preeti Thakkar sold a 3.96% stake (Sep 30, 2026) and the company licensed Vitamin B12 fortification technology from VIT (Sep 8, 2026) — a core-segment initiative with no quantifiable revenue impact yet disclosed — while subsidiary FESPL raised ₹21.53 lakh via a private placement and set up an ESOP pool, developments relevant to the Environment segment's capital base rather than this quarter's P&L.

5 Nov 2026, 01:00 pm

Corporate Events

Board MeetingFERMENTA
2026
5Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingFERMENTA
2026
11Aug

Board Meeting

Submission of the Annual Report for the financial year 2025-…

BSE Filing ↗
DividendFERMENTA
2026
5Aug

₹3.75 / share

BSE Filing ↗
Board MeetingFERMENTA
2026
26May

Board Meeting

The board meeting is scheduled to consider and approve audit…

BSE Filing ↗
Board MeetingFERMENTA
2026
9Feb

Board Meeting

consider and approve unaudited financial results

BSE Filing ↗
Board MeetingFERMENTA
2025
10Dec

Board Meeting

Raising of funds

BSE Filing ↗
Board MeetingFERMENTA
2025
11Nov

Board Meeting

consider and approve unaudited financial results

BSE Filing ↗
Board MeetingFERMENTA
2025
12Aug

Board Meeting

consider and approve unaudited financial results (standalone…

BSE Filing ↗
Board MeetingFERMENTA
2025
28May

Board Meeting

consider and approve audited financial results (standalone a…

BSE Filing ↗
Board MeetingFERMENTA
2025
11Feb

Board Meeting

consider and approve the unaudited financial results

BSE Filing ↗
Board MeetingFERMENTA
2024
14Nov

Board Meeting

consider and approve unaudited financial results for the qua…

BSE Filing ↗
Board MeetingFERMENTA
2024
12Aug

Board Meeting

Consider and approve Unaudited Financial Results

BSE Filing ↗
Board MeetingFERMENTA
2024
27May

Board Meeting

Consider and approve audited financial results of the Compan…

BSE Filing ↗
DividendFERMENTA
2023
22Sep

₹1.25 / share

BSE Filing ↗
Board MeetingFERMENTA
2023
11Aug

Board Meeting

consider and approve the unaudited financial results

BSE Filing ↗